May 7 2017

The Significant Participation of Clay B. Siegall in curing Cancer.

Clay B. Siegall is among the most accomplished professionals in the pharmaceutical industry. He has been leading various research undertakings that are focused on determining an idea cure for cancer. Clay is an alumnus of the George Washington University where he was awarded a Ph.D. in genetics. The scientist has co-founded a research and pharmaceuticals organization that is known as Settle Genetics, and he currently acts as its CEO and president. Since 1998, the firm has been focused on research, scientific creations, and development of improved drugs. Siegall has been leading the team of researchers who work at his company in the development of medications that can heal cancer. The company has successfully discovered several of antibody-drug conjugates (ADCs) that save the lives of cancer patients. Seattle Genetics’s first ADC was known as ADCETRIS®, and it got the approval of the FDA in 2011. The firm has managed to distribute the drug in over 65 countries by partnering with Takeda Pharmaceutical Company.

 

Seattle Genetics has different types of strategic licenses that are needed in the global manufacture and distribution of ADCs. The company’s main drugs are Genentech, AbbVie, Pfizer, and GlaxoSmithKline. All these brands are currently sold across the globe, and they have earned Seattle Genetics more than $350 million. Siegall has led the company in manufacturing more than 20 ADCs using the great technology that it has developed. Seattle Genetics has also been producing its drugs externally by working with various pharmaceutical companies. Clay has developed outstanding financing strategies for the Seattle Genetics. The firm held its first public offering in 2001, and to date, it has raised more than $1.2 billion.

 

Clay Siegall had a long career before the founding of Seattle Genetics. He kicked off his profession by serving as a researcher at National Cancer Institute as from 1988. In 1991, Clay got another job at Bristol-Myers Squibb Pharmaceutical Research Institute and served the organization until 1997. Top corporations such as Ultragenyx Pharmaceutical, BioPharmaceutica, and Washington Roundtable have appointed him to serve on their boards. Siegall has developed various drugs, and he holds more than 15 patents for his work.